Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update

Key Points

• Genenta Science S.p.A. experienced a significant increase in short interest, rising by 69.2% to 6,600 shares as of July 15th.
• Institutional investors hold 15.13% of Genenta Science's stock, with notable increases in holdings from Citadel Advisors and Allianz SE.
• Shares of Genenta Science traded up 2.2% recently, with a current price of $3.78 and a 52-week range between $2.74 and $7.28.

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA - Get Free Report) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 6,600 shares, agrowthof69.2% from the June 30th total of 3,900 shares. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily volume of 12,300 shares, the days-to-cover ratio is currently 0.5 days.

Genenta Science Trading Down 0.4%

NASDAQ GNTA traded down $0.02 on Thursday, reaching $3.79. 886 shares of the stock traded hands, compared to its average volume of 4,633. Genenta Science has a 12 month low of $2.74 and a 12 month high of $7.28. The company has a fifty day moving average price of $3.78 and a 200-day moving average price of $3.91.

Institutional Trading of Genenta Science

Several institutional investors and hedge funds have recently made changes to their positions in GNTA. Citadel Advisors LLC bought a new position in Genenta Science in the fourth quarter worth about $46,000. Algebris UK Ltd boosted its holdings in shares of Genenta Science by 122.2% in the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after buying an additional 55,000 shares in the last quarter. Finally, Allianz SE grew its position in shares of Genenta Science by 126.2% in the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock worth $927,000 after buying an additional 130,300 shares during the last quarter. 15.13% of the stock is currently owned by institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.